The Hanover Insurance Group Sees Q4 Catastrophe Losses ~$190M
- The Hanover Insurance Group, Inc. (NYSE:THG) today announced a preliminary estimate for fourth quarter catastrophe losses of approximately $190 million, before taxes, or 13.9 points of net earned
‘Smartphone vendors cautious about 2023 sales goals’ -DigiTimes
https://www.digitimes.com/news/a20230118PD213.html
Sonnet BioTherapeutics Announces Pharmacokinetic And Pharmacodynamic Data In A Phase 1 Dose-Escalation Trial Of SON-1010; Says ‘PK data shows an extended half-life of SON-1010 of approximately 112 hours, compared to 12 hours for rhIL-12’
24 healthy volunteers have been dosed in study SB102 to assess the safety, PK, and PD of SON-1010 without the background of prior chemotherapy
PK data shows an extended half-life of SON-1010 of approximately 112
American National Q4 EPS $0.76 Misses $0.87 Estimate
American National (NASDAQ:AMNB) reported quarterly earnings of $0.76 per share which missed the analyst consensus estimate of $0.87 by 12.64 percent. This is a 27.62 percent decrease over earnings of $1.05 per share from
XORTX Announces Topline Results From XRX-OXY-101 Clinical Trial
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat
PLBY Group Secures $25M Capital Commitment
PLBY Group, Inc. (NASDAQ:PLBY) ("PLBY Group" or the "Company") announced today that it secured a $25 million capital commitment (the "Investment") led by Michael Serruya at Serruya
BriaCell Announces End Of Phase II Meeting With FDA For Bria-IMT Combination In Advanced Metastatic Breast Cancer; FDA Has Agreed On Primary Endpoint
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast
Fulton Financial Q4 EPS $0.47 Misses $0.50 Estimate
Fulton Financial (NASDAQ:FULT) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.50 by 6 percent. This is a 27.03 percent increase over earnings of $0.37 per share from the